Cha2ds2vasc Calculator

Estimate your cha2ds2vasc with our free cardiovascular system calculator. See reference ranges, risk factors, and next-step guidance.

Share this calculator

X Facebook LinkedIn

Formula

CHA2DS2-VASc = C + H + A2 + D + S2 + V + A + Sc (max 9)

C = Congestive heart failure (1 pt), H = Hypertension (1 pt), A2 = Age 75+ (2 pts), D = Diabetes (1 pt), S2 = Stroke/TIA/thromboembolism (2 pts), V = Vascular disease (1 pt), A = Age 65-74 (1 pt), Sc = Sex category female (1 pt). Score determines stroke risk and anticoagulation recommendation.

Worked Examples

Example 1: Low-Risk Male Patient

Problem: A 55-year-old male with newly diagnosed paroxysmal atrial fibrillation. No hypertension, diabetes, heart failure, vascular disease, or prior stroke. Calculate CHA2DS2-VASc score.

Solution: C (CHF): 0\nH (Hypertension): 0\nA2 (Age >=75): 0\nD (Diabetes): 0\nS2 (Stroke/TIA): 0\nV (Vascular disease): 0\nA (Age 65-74): 0\nSc (Sex - male): 0\nTotal CHA2DS2-VASc = 0

Result: Score: 0 (Low Risk, ~0% annual stroke rate). No anticoagulation recommended.

Example 2: High-Risk Female Patient

Problem: A 78-year-old female with atrial fibrillation, hypertension, type 2 diabetes, prior TIA, and history of MI. Calculate CHA2DS2-VASc score.

Solution: C (CHF): 0\nH (Hypertension): +1\nA2 (Age >=75): +2\nD (Diabetes): +1\nS2 (Prior TIA): +2\nV (Prior MI): +1\nA (Age 65-74): 0 (superseded by age >=75)\nSc (Female): +1\nTotal CHA2DS2-VASc = 8

Result: Score: 8 (High Risk, ~6.7% annual stroke rate). Oral anticoagulation with DOAC strongly recommended.

Frequently Asked Questions

What is the CHA2DS2-VASc score and what is it used for?

The CHA2DS2-VASc score is a clinical prediction tool used to estimate the annual risk of stroke in patients with non-valvular atrial fibrillation. It was developed as an improvement over the original CHADS2 score to better identify truly low-risk patients who do not need anticoagulation. The acronym represents Congestive heart failure (1 point), Hypertension (1 point), Age 75 or older (2 points), Diabetes mellitus (1 point), Stroke/TIA/thromboembolism (2 points), Vascular disease (1 point), Age 65-74 (1 point), and Sex category female (1 point). The maximum score is 9. It is the most widely recommended stroke risk stratification tool in current international guidelines for atrial fibrillation management.

How does the CHA2DS2-VASc score guide anticoagulation therapy?

The CHA2DS2-VASc score directly determines whether oral anticoagulation should be initiated in patients with atrial fibrillation. According to current ESC and AHA/ACC guidelines, a score of 0 in men (or 1 in women where the only point is female sex) indicates low stroke risk, and no antithrombotic therapy is recommended. A score of 1 in men represents a zone where anticoagulation should be considered based on individual assessment. A score of 2 or higher in men (3 or higher in women) strongly recommends oral anticoagulation, preferably with a direct oral anticoagulant (DOAC) such as apixaban, rivaroxaban, dabigatran, or edoxaban rather than warfarin. Aspirin alone is no longer recommended for stroke prevention in atrial fibrillation as it provides minimal benefit with significant bleeding risk.

Why does female sex receive a point in the CHA2DS2-VASc score?

Female sex was included in the CHA2DS2-VASc score because epidemiological studies showed that women with atrial fibrillation have a higher relative risk of stroke compared to men, particularly in older age groups and when other risk factors are present. However, the role of female sex as an independent risk factor has been debated extensively. Current guidelines clarify that female sex is a stroke risk modifier rather than an independent risk factor, meaning it increases risk only when other risk factors are present. A woman with atrial fibrillation and no other risk factors (CHA2DS2-VASc of 1 based on sex alone) is considered low risk and does not require anticoagulation. This distinction is important to avoid unnecessary treatment in young, otherwise healthy women with lone atrial fibrillation.

What qualifies as vascular disease in the CHA2DS2-VASc score?

Vascular disease in the CHA2DS2-VASc score encompasses several conditions affecting the arterial system. Specifically, it includes prior myocardial infarction, peripheral arterial disease (PAD) documented by ankle-brachial index, angiography, or prior revascularization, and aortic plaque identified on imaging. Coronary artery disease diagnosed by angiography showing significant stenosis also qualifies, even without prior myocardial infarction. Some studies have also included carotid artery disease with significant stenosis. The rationale for including vascular disease is that these conditions share common pathophysiology with cardioembolic stroke including endothelial dysfunction, atherosclerosis, and prothrombotic states. Simple coronary artery disease risk factors such as hyperlipidemia alone do not qualify as vascular disease for this scoring system.

How accurate is the CHA2DS2-VASc score at predicting stroke?

The CHA2DS2-VASc score has moderate discriminative ability for predicting stroke, with C-statistics typically ranging from 0.55 to 0.70 across validation studies. Its primary strength lies in its excellent ability to identify truly low-risk patients (score of 0) who have annual stroke rates below 1 percent, making it highly effective as a screening tool for anticoagulation decisions. The score performs less well at discriminating between moderate and high-risk categories, as actual stroke rates do not increase linearly with each point. Large validation studies including over 170,000 patients have confirmed that the score reliably categorizes patients into clinically meaningful risk groups. However, individual patient risk can vary based on factors not captured in the score, including left atrial size, atrial fibrillation burden, and biomarker levels.

What is the difference between CHADS2 and CHA2DS2-VASc scores?

The original CHADS2 score included only five risk factors: Congestive heart failure (1 point), Hypertension (1 point), Age over 75 (1 point), Diabetes (1 point), and Stroke/TIA (2 points), with a maximum of 6 points. The CHA2DS2-VASc score expanded on this by adding three additional risk factors: vascular disease (1 point), age 65-74 (1 point), and female sex (1 point), while also increasing the age over 75 component to 2 points, creating a maximum score of 9. The key improvement was the ability to reclassify patients in the CHADS2 score of 0 or 1 categories, where many patients were found to have annual stroke rates exceeding 1 percent when CHA2DS2-VASc factors were considered. This reduced the intermediate risk category where treatment decisions were unclear.